AzTrials
AzTrials

Airway ObstructionNCT06545903

Supraglottic Airways for Entrapped Trauma Patients

A study testing LMA Supreme, SLIPA and I-gel in people with Airway Obstruction, run by Uniwersytet Radomski im. Kazimierza Pułaskiego at 1 site in Poland.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The aim of this clinical trial is to evaluate four supraglottic airway devices for ventilation in a simulated condition of an entrapped trauma patient with simultaneous cervical spine immobilisation. All the studied devices are evaluated by fully-qualified and experienced paramedics (both male and female). Read more about this study

Who is it for?
Ages 25 to 55 years
Conditions the study is for
Airway Obstruction
What is being tested?
LMA Supreme, SLIPA and I-gel
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
50 participants
Where
1 sitePoland
Study dates
1 Jul 2024to 1 May 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 25 to 55 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • fully-qualified paramedics
  • at least four years of practice after finishing paramedic training
  • active (working) paramedics

Who cannot join

  • paramedics in training
  • retired paramedics
  • lack of written informed consent

Trial locations and contacts

1 site in 1 country.

Poland1 site
  • University of Radom

    Radom, Masovian Voivodeship, 26-600

Other trials in Poland

About this study

Official title: Supraglottic Airway Devices for Airway Management of Entrapped Trauma Patients - an Evaluation of Four Devices in a Simulated Condition With Simultaneous Cervical Spine Immobilisation - a Randomised, Controlled Trial

The aim of this clinical trial is to evaluate four supraglottic airway devices for ventilation in a simulated condition of an entrapped trauma patient with simultaneous cervical spine immobilisation. All the studied devices are evaluated by fully-qualified and experienced paramedics (both male and female). The main questions it aims to answer are:

  1. Which device requires the shortest time required to achieve a successful ventilation?
  2. What is the first attempt success rate of the studied devices?
  3. Which device is the easiest to use and the most user-friendly? Study participants will evaluate four different supraglottic devices in a restricted access to the entrapped trauma patient's airway. The maximum number of insertion attempts is limited to three per device.
Read the detailed description

A 10-minute lecture will be delivered before the start of the study. It will explain how to use the studied devices. Following the lecture all participants will be able to familiarise themselves with the equipment and practice for 30 minutes. A skill station will be set up containing an intubation manikin AT Kelly Torso (Laerdal Medical AS, Stavanger, Norway). A reduced movement of the cervical spine will be achieved by application of a Patriot® cervical collar (Össur hf., Reykjavik, Iceland). After completion of the initial practice the intubation manikin with the cervical collar on will be placed on and secured to the driver's seat of a medium-sized passenger car (FIAT S.p.A., Turin, Italy). The car will then be positioned on its left side and secured in place by firemen from a local fire brigade. The access to the manikin will only be allowed from the front i.e. through the opening created after removal of the windscreen. A single digit number will be allocated to each of the four studied devices i.e. 1 for the SLIPA device, 2 for the I-gel, 3 for the LMA Supreme and 4 for the LTS. Each study participant will be asked to randomly give a number (either 1, 2, 3 or 4) and will then be given the corresponding airway device to use. The maximum number of insertion attempts will be limited to three per device. The time required to insert the device and achieve a successful ventilation (Tiv) will be recorded. It will be measured using a stopwatch of a mobile phone (Apple Inc., Cupertino, California, USA). Efficacy of insertion/ventilation and the ease of use by the operator will also be assessed. The latter will be measured using an 11-point numerical rating scale (NRS) where 0 corresponds to a very difficult to use device and 10 indicates an easy to use and user-friendly device. A manual resuscitator (Ambu A/S, Ballerup, Denmark) will be used for ventilation and will be readily available to the paramedics. The study participants will perform all insertions with each of the four supraglottic airway devices. A failed insertion and ventilation is defined as an attempt during which the manikin cannot be ventilated or an attempt that lasted longer than 120 seconds. Only those who failed to ventilate will be allowed another attempt. All the obtained data will be analysed using Microsoft Office Excel 2021 spreadsheet (Microsoft Corporation, Redmond, WA, USA). The Kolmogorov-Smirnov test is utilised to determine whether the analysed variables matched the characteristics of a normal distribution. A paired Student t-test and the Wilcoxon signed-rank test will be used for data analysis. Based on our previous unpublished pilot study and assuming that the overall success rate of intubation in patients with a difficult airway would be 90% (α =0.05, 2-sided, β =0.1), 46 participants will be required. The final adjusted sample size, allowing a drop-out rate of about 10%, is 50 and this is the final number of participants enrolled into the study. A p-value of less than 0.05 (p<0.05) is considered statistically significant.

Being tested
LMA Supreme, SLIPA, I-gel, AuraGain
Keywords
Entrapped Trauma Patients, Airway Management, Paramedics
Medical subject headings
Airway Obstruction

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • LMA SupremeDevice

    The device is inserted and the manikin ventilated

  • SLIPADevice

    The device is inserted and the manikin ventilated

  • I-gelDevice

    The device is inserted and the manikin ventilated

  • AuraGainDevice

    The device is inserted and the manikin ventilated

Study groups in NCT06545903
Study groupRoleWhat they receive
LMA Supreme GroupActive comparatorParamedics using the LMA Supreme airway device
Receives: Device: LMA Supreme
Other Supraglottic Airway GroupExperimentalParamedics using other supraglottic devices
Receives: Device: SLIPA; Device: I-gel; Device: AuraGain

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Successful ventilation time

    The time required to insert the device and achieve a successful ventilation

    Measured: During procedure: 120 seconds

Secondary outcomes (2)
  1. First attempt success rate of ventilation

    The efficacy of an evaluated supraglottic airway device

    Measured: During procedure: 120 seconds

  2. The ease of use and user-friendliness

    Device evaluation using the numerical rating scale (NRS). It is an 11-point scale where 0 corresponded to a very difficult to use device and 10 indicated an easy to use and user-friendly device.

    Measured: During procedure: 120 seconds

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Aug 2024
  2. Study start1 Jul 2024
  3. Primary completion1 Sep 2024
  4. Study completion1 May 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Masking
Single blind
Who is masked
Participant
Enrolment
50 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06545903
Sponsor's protocol ID
3/2024
Status last verified
May 2025
First submitted
16 Jul 2024
Last updated
6 May 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing LMA Supreme, SLIPA and I-gel in people with Airway Obstruction, run by Uniwersytet Radomski im. Kazimierza Pułaskiego at 1 site in Poland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 6 May 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Poland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Successful ventilation time (time frame: During procedure: 120 seconds). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 May 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in